Danaher Corporation $DHR Position Raised by Mirador Capital Partners LP

Mirador Capital Partners LP grew its position in shares of Danaher Corporation (NYSE:DHR) by 28.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 29,355 shares of the conglomerate’s stock after acquiring an additional 6,492 shares during the quarter. Mirador Capital Partners LP’s holdings in Danaher were worth $6,504,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of DHR. BlackRock Inc. bought a new stake in Danaher in the 2nd quarter valued at about $10,492,520,000. Jupiter Topco LLC bought a new position in Danaher in the 2nd quarter worth about $1,456,317,000. Generation Investment Management LLP acquired a new stake in shares of Danaher in the second quarter valued at approximately $1,287,949,000. Bank of America Corp DE bought a new stake in shares of Danaher during the second quarter valued at approximately $993,846,000. Finally, Legal & General Group Plc bought a new stake in shares of Danaher during the second quarter valued at approximately $801,056,000. Institutional investors own 79.05% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on DHR. UBS Group initiated coverage on Danaher in a report on Wednesday, September 9th. They issued a “buy” rating and a $250.00 price objective for the company. TD Cowen cut their target price on Danaher from $240.00 to $236.00 and set a “buy” rating on the stock in a research note on Wednesday, July 22nd. Wells Fargo & Company reduced their price target on Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 22nd. The Goldman Sachs Group increased their price objective on shares of Danaher from $210.00 to $250.00 and gave the company a “buy” rating in a report on Monday, September 21st. Finally, Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a research note on Saturday. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $235.23.

Danaher Price Performance

NYSE DHR opened at $220.15 on Friday. The company has a 50 day simple moving average of $211.38 and a 200-day simple moving average of $194.62. The firm has a market capitalization of $154.76 billion, a price-to-earnings ratio of 39.10, a price-to-earnings-growth ratio of 2.71 and a beta of 0.76. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25.

Danaher (NYSE:DHR) last posted its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, topping the consensus estimate of $1.85 by $0.09. The firm had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%. During the same period in the previous year, the company earned $0.77 EPS. The company’s revenue for the quarter was up 5.5% on a year-over-year basis. Equities research analysts predict that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Wednesday, September 30th. Danaher’s dividend payout ratio is 28.42%.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.